Mark Barberio appointed
Chairman of the Board of Directors effective at 2021 Annual General
Meeting
DUBLIN, April 27, 2021 /CNW/ -- Endo International
plc (NASDAQ: ENDP) ("Endo" or the "Company") today announced that
Mark Barberio, who currently serves
as an independent member of Endo's Board of Directors (the
"Board"), has been appointed Chairman of the Board effective at the
Company's 2021 Annual General Meeting. Mr. Barberio's appointment
is part of Endo's ongoing Board succession process, which has also
included adding two new Board members since the Company's 2020
Annual General Meeting. In addition, Paul
Campanelli, who has served as Chairman of the Board since
2019 and who served as President and Chief Executive Officer from
2016 to 2020, will retire from the Board upon the expiration of his
current term at the Company's 2021 Annual General Meeting.
Finally, Roger Kimmel, who has been
Senior Independent Director since 2019 and who served as Chairman
of the Board from 2014 to 2019, will also retire from the Board
upon the expiration of his current term.
"I am honored to have been appointed Chairman during this
important period of Endo's transformation," said Mr. Barberio. "I
have seen firsthand the Board and management team's commitment to
taking the actions necessary to deliver sustainable value over the
long-term. On behalf of the Board, I want to thank Paul and Roger
for their many years of service and dedication to Endo. Their
leadership, insights and perspectives have been invaluable as Endo
has advanced its strategic priorities."
"Since joining the Board, Mark has provided valuable strategic
perspectives and expertise. I look forward to working closely with
him as we continue delivering life-enhancing products," said
Blaise Coleman, President and Chief
Executive Officer of Endo. "I also want to thank Roger for his many
contributions during his years of service on the Board and Paul for
his invaluable leadership and critical guidance."
Mr. Barberio has been a member of the Board since February 2020. He has been a Principal of
Markapital, LLC since May 2013 and
currently serves as a Director of Gibraltar Industries, Inc. and
Life Storage, Inc., where he has been Non-Executive Chairman since
May 2018.
About Endo
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company
committed to helping everyone we serve live their best life through
the delivery of quality, life-enhancing therapies. Our decades of
proven success come from a global team of passionate employees
collaborating to bring the best treatments forward. Together, we
boldly transform insights into treatments benefiting those who need
them, when they need them. Learn more at www.endo.com or
connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 and the relevant Canadian securities legislation,
including, but not limited to, the statements by Messrs. Barberio
and Coleman and other statements regarding the Company and changes
to the Board of Directors. Statements including words such as
"believes," "expects," "anticipates," "intends," "estimates,"
"plan," "will," "may," "look forward," "intend," "guidance,"
"future" or similar expressions are forward-looking statements.
Because these statements reflect Endo's current views, expectations
and beliefs concerning future events, they involve risks and
uncertainties. Although Endo believes that these forward-looking
statements and information are based upon reasonable assumptions
and expectations, readers should not place undue reliance on them,
or any other forward-looking statements or information in this news
release. Investors should note that many factors, as more fully
described in the documents filed by Endo with the Securities and
Exchange Commission and with securities regulators in Canada on the System for Electronic Document
Analysis and Retrieval, including under the caption "Risk Factors"
in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as
otherwise enumerated herein or therein, could affect Endo's future
results and could cause Endo's actual results to differ materially
from those expressed in forward-looking statements contained in
this communication. The forward-looking statements in this press
release are qualified by these risk factors. Endo assumes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise, except as may be required under applicable securities
laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/endo-implements-board-succession-plan-301278384.html
SOURCE Endo International plc